摘要
目的：回顾性研究了依曲替酯治疗４９例角化性疾病（银屑病３３例，毛发红糠疹６例，鱼鳞病３例和扁平苔藓７例）的疗效及不良反应等。方法：本研究的４９例患者均服用依曲替酯，剂量为０．５～１．４ｍｇ／（ｋｇ·ｄ）。结果：痊愈率４９．０％（２４／４９），有效率７９．６％（３９／４９）。８５．７％（４２／４９）患者出现轻微可耐受的不良反应。结论：依曲替酯对银屑病和角化性疾病均有较好的疗效，皮肤和粘膜的不良反应常见，但轻微短暂，不影响治疗。
OBJECTIVE:To study retrospectively the effect and ADRs of etretinate in 49 patients of keratinization, including psoriasis 33 cases, pityriasis rubra pilaris 6 cases, ichthyosis 3 cases and lichen planus 7 cases. METHODS:Patients were treated with etretinate in a dose 0.5～1.4mg/(kg·d).RESULTS:A curative rate of 49.0%(24/49) and an effective rate of 79.6%(39/49) were obtained and 85.7%(42/49) of the patients had mild or tolerable ADRs. CONCLUSION:Etretinate was effective in the treatment of psoriasis and disorders of keratinization. ADRs on the skin and mucous membranes were always observed during treatment, but were mild and transient and the treatment wasn't affected.
出处
《中国新药杂志》
CAS
CSCD
1998年第2期105-107,共3页
Chinese Journal of New Drugs
关键词
依曲替酯
银屑病
毛发红糖疹
治疗
药理
Etretinate
Psoriasis
Pityriasis rubra pilaris
Ichthyosis
Lichen planus
